GEN Exclusives

More »

GEN News Highlights

More »
Oct 26, 2007

Coley Receives $3M from GSK with Start of Phase III NSCLC Study

  • Coley Pharmaceutical obtained a $3 million milestone payment from GlaxoSmithKline (GSK). The payment is associated with GSK’s initiation of its Phase III trial in non-small-cell lung cancer (NSCLC) investigating an immunotherapeutic cancer vaccine containing Coley’s VaxImmune™ vaccine adjuvant.

    In June 2007, GSK began a Phase III trial in lung cancer to evaluate MAGE-A3 antigen-specific cancer immunotherapeutic (MAGE-A3 ASCI) in patients with early-stage, completely resected NSCLC. VaxImmune is one of the components of MAGE-A3 ASCI, intended to increase an antitumor immune response.

    VaxImmune is Coley’s TLR9 agonist designed to induce both an enhanced antibody response and a potent killer T-cell immune response when used in conjunction with vaccines to achieve and sustain a clinical response without compromising safety. Coley has granted GSK worldwide licenses for the use of VaxImmune in the development of vaccines for certain cancers and infectious diseases.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?